Geographic distribution of HTLV‐I and identification of a new high‐risk population
Paul H. Levine(National Cancer Institute), W. Carl Saxinger(National Cancer Institute), Elizabeth M. Maloney(National Institutes of Health), E. M. Murphy(National Institutes of Health), Jeffrey W. Clark(Massachusetts General Hospital), Marjorie Robert‐Guroff(National Cancer Institute), Robert C. Gallo(University of South Florida), William A. Blattner(Unknown), Robert E. Tarone(National Cancer Institute)
Cited by 80
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k